Company Filing History:
Years Active: 2001
Title: Klaus Matthey: Innovator in Pharmaceutical Formulations
Introduction
Klaus Matthey, an accomplished inventor based in Jena, Germany, is known for his contributions to the field of pharmaceutical technology. With a focus on creating innovative preformulations, he has significantly advanced the production of low-dose solid and semi-solid medications.
Latest Patents
Klaus Matthey holds a patent for "Homogeneous preformulations containing high concentrations of steroids, for producing low-dose solid and semi-solid pharmaceutical preparations." This patent describes a unique method for creating a steroid-containing preformulation that ensures a consistent dosage. The formulation consists of at least one steroid within a range of 0.001 to 1 percent by weight, utilizing a method that involves dissolving steroids in a solvent and dispersing adjuvant particles to create a stable suspension. The innovative approach maximizes therapeutic efficacy while minimizing dosing challenges in pharmaceutical preparations.
Career Highlights
Matthey is associated with Jenapharm GmbH & Co. KG, a company that specializes in pharmaceutical research and development. His work has been instrumental in refining the methodologies used in the production of steroid formulations, ultimately contributing to more effective treatment options for patients. He has garnered recognition for his innovative approaches and practical applications of his research.
Collaborations
Klaus Matthey has worked alongside talented colleagues such as Detlef Grawe and Peter Hoesel. Their collaborative efforts have helped advance the development of pharmaceutical technologies, bolstering the efficacy and safety of medications available to medical professionals.
Conclusion
In summary, Klaus Matthey's innovative spirit and dedication to pharmaceutical advancements have led to significant breakthroughs in steroid formulation. His patent represents a vital step towards enhancing drug delivery systems, benefiting both healthcare providers and patients alike. As he continues to push the boundaries of pharmaceutical formulation, his contributions are sure to leave a lasting impact on the industry.